Aims Aims Tocomparetheimpactof industry-
To comparetheimpactof industrylinked andnon-industrylinkedarticles. linked andnon-industrylinkedarticles.
Method Method We comparedarticles on
We comparedarticles on sertraline beingcoordinatedbya medical sertraline beingcoordinatedbya medical writingagencywitharticlesnotcoordinated writingagencywitharticlesnotcoordinated inthisway. We calculatednumbers of inthisway. We calculatednumbersof Medline-listedarticlesper author, journal Medline-listedarticlesper author, journal impactfactors, literature profiles and impactfactors, literature profiles and citationrates of both sets of articles. citationrates of both sets of articles.
Results Results Non-agency-linked articles on
Non-agency-linked articles on sertraline had an average of 2.95 authors sertraline had an average of 2.95 authors per article, a mean length of 3.4 pages, a per article, a mean length of 3.4 pages, a mean Medline listing of 37 articles per mean Medline listing of 37 articles per author (95% CI 27^47) and a mean author (95% CI 27^47) and a mean literature profile of 283 per article (95% literature profile of 283 per article (95% CI130^435). Agency-linked articles on CI130^435). Agency-linked articles on sertraline had an average of 6.6 authors sertraline had an average of 6.6 authors per article, a mean length of10.7 pages, a per article, a mean length of10.7 pages, a mean Medline listing of 70 articles per mean Medline listing of 70 articles per author (95% CI 62^79) and a mean author (95% CI 62^79) and a mean literature profile of1839 per article (95% literature profile of1839 per article (95% CI1076^2602).The citation rate for CI1076^2602).The citation rate for agency articles was 20.2 (95% CI13.4âgency articles was 20.2 (95% CI13.42 7.0) and for non-agency articles it was 27.0) and for non-agency articles it was 3.7 (95% CI 3.3^8.1). 3.7 (95% CI 3.3^8.1).
Conclusions Conclusions The literature profiles
The literature profiles and citation rates of industry-linked and and citation rates of industry-linked and non-industry-linked articles differ.The non-industry-linked articles differ.The emerging style of authorship in industryemerging style of authorship in industrylinked articles can deliver good-quality linked articles can deliver good-quality articles, but it raises concerns for the articles, but it raises concerns for the scientific base of therapeutics. scientific base of therapeutics.
Declaration of interest Declaration of interest D.H. has had
D.H. has had consultancies or other links with all major consultancies or other links with all major pharmaceutical companies. pharmaceutical companies.
Traditionally scientific authors generate, Traditionally scientific authors generate, analyse and have access to raw data and analyse and have access to raw data and prepare an article that disinterested prepare an article that disinterested observers would accept reflects an approobservers would accept reflects an appropriate interpretation of those data. Authorpriate interpretation of those data. Authorship has been changing, however, and ship has been changing, however, and journals now accept that articles may be journals now accept that articles may be authored by individuals who have made a authored by individuals who have made a substantial contribution to the conception substantial contribution to the conception and design or the acquisition of data or and design or the acquisition of data or analysis and interpretation of data in a analysis and interpretation of data in a study, or who have drafted or critically study, or who have drafted or critically revised the intellectual content of an article revised the intellectual content of an article and who have approved the final version of and who have approved the final version of the published article (International Comthe published article (International Committee of Medical Journal Editors, 2000; mittee of Medical Journal Editors, 2000; Rennie Rennie et al et al, 2002) . This new authorship , 2002) . This new authorship matrix is consistent with many articles matrix is consistent with many articles being ghostwritten (Davidoff being ghostwritten (Davidoff et al et al, 2001) . , 2001). Unacknowledged editorial or writing Unacknowledged editorial or writing assistants to academic authors -so-called assistants to academic authors -so-called ghostwriters -are often employed by ghostwriters -are often employed by medical communication agencies working medical communication agencies working for pharmaceutical companies. Efforts have for pharmaceutical companies. Efforts have been made to quantify the extent to which been made to quantify the extent to which ghostwriting is happening, with Flanagin ghostwriting is happening, with Flanagin et al et al (1998) reporting that up to 11% of (1998) reporting that up to 11% of articles published in six peer-reviewed articles published in six peer-reviewed journals in 1996 involved the use of ghostjournals in 1996 involved the use of ghostwriters. writers.
There are a number of delicate issues There are a number of delicate issues that need to be teased out in this area, that need to be teased out in this area, ranging from the practicalities of regulating ranging from the practicalities of regulating authorship to the more profound questions authorship to the more profound questions of whether ghostwriting is an unfortunate of whether ghostwriting is an unfortunate accidental development in the scientific accidental development in the scientific enterprise or whether it reflects some enterprise or whether it reflects some fundamental aspect of the way modern fundamental aspect of the way modern science is conducted. There can be few if science is conducted. There can be few if any of these issues or questions, however, any of these issues or questions, however, that would not benefit from some quantifithat would not benefit from some quantification of what is happening. Against this cation of what is happening. Against this background we have sought to quantify background we have sought to quantify the literature profile of articles on one drug, the literature profile of articles on one drug, sertraline, that were in production in 1998. sertraline, that were in production in 1998.
METHOD METHOD
This article distinguishes between traditional This article distinguishes between traditional and non-traditional authorship on the basis and non-traditional authorship on the basis of a judgement as to whether the authors of a judgement as to whether the authors are free in a traditional manner to share are free in a traditional manner to share with others the raw data from studies they with others the raw data from studies they author. We have assumed that authors author. We have assumed that authors working on company-sponsored articles working on company-sponsored articles are, in general, not at liberty to share are, in general, not at liberty to share proprietary raw data and are even less proprietary raw data and are even less likely to do so if they have not seen the likely to do so if they have not seen the raw data in the first instance. By raw data raw data in the first instance. By raw data here is meant untabulated data; tabulation here is meant untabulated data; tabulation is arguably a primary and key act of is arguably a primary and key act of authorship. In pharmaceutical-companyauthorship. In pharmaceutical-companysponsored clinical trials, this initial tabulasponsored clinical trials, this initial tabulation is invariably performed either within tion is invariably performed either within the company or within a contract research the company or within a contract research organisation that passes on tabulated data organisation that passes on tabulated data and trial reports to medical writing and trial reports to medical writing agencies. This practice, almost by definiagencies. This practice, almost by definition, gives rise to a non-traditional form tion, gives rise to a non-traditional form of authorship. In contrast, we have asof authorship. In contrast, we have assumed that individuals who conduct studies sumed that individuals who conduct studies of their own design, regardless of funding of their own design, regardless of funding source, can share raw data, if necessary. source, can share raw data, if necessary.
We have used two data sources:
We have used two data sources: Medline and E Medline and EMBASE MBASE literature retrieval literature retrieval services searching for the word sertraline services searching for the word sertraline in the titles of articles from 1998, which in the titles of articles from 1998, which were scrutinised for articles referring to were scrutinised for articles referring to the therapeutic uses of sertraline; and a the therapeutic uses of sertraline; and a document prepared for Pfizer Pharmadocument prepared for Pfizer Pharmaceuticals by Current Medical Directions ceuticals by Current Medical Directions (CMD) on 29 January 1999, which gives (CMD) on 29 January 1999, which gives a worldwide status update for 85 articles a worldwide status update for 85 articles on Pfizer's antidepressant sertraline, some on Pfizer's antidepressant sertraline, some of which had been published in 1998 and of which had been published in 1998 and others subsequently in 1999, 2000 or early others subsequently in 1999, 2000 or early 2001. The CMD document was made 2001. The CMD document was made available to us on a non-confidential basis available to us on a non-confidential basis in the course of legal proceedings. in the course of legal proceedings.
Current Medical Directions is a medical Current Medical Directions is a medical information company, based in New York information company, based in New York and set up in 1990 to deliver scientifically and set up in 1990 to deliver scientifically accurate information strategically develaccurate information strategically developed for specific target audiences (http:// oped for specific target audiences (http:// www.cmdconnect.com). This agency writes www.cmdconnect.com). This agency writes up studies, review articles, abstracts, jourup studies, review articles, abstracts, journal supplements, product monographs, exnal supplements, product monographs, expert commentaries and textbook chapters. pert commentaries and textbook chapters. It conducts meta-analyses and organises It conducts meta-analyses and organises journal supplements, satellite symposia journal supplements, satellite symposia and consensus conferences, as well as and consensus conferences, as well as advisory boards for its clients. advisory boards for its clients.
The CMD document indicates that The CMD document indicates that CMD was coordinating articles on sertra-CMD was coordinating articles on sertraline. These articles appear to involve proline. These articles appear to involve proprietary data in almost all instances. There prietary data in almost all instances. There 2 2 2 2 In the non-CMD series, the majority series. In the non-CMD series, the majority are reports of studies not supported by are reports of studies not supported by Pfizer and only one appears to have inPfizer and only one appears to have involved the generation of proprietary data; volved the generation of proprietary data; accordingly we have assumed that these accordingly we have assumed that these authors are in a position to share raw data authors are in a position to share raw data if requested. if requested.
We have attempted to estimate the We have attempted to estimate the impact of these two different groups of impact of these two different groups of articles as follows. The impact factor for articles as follows. The impact factor for each journal was established using each journal was established using Journal Journal Citation Report Citation Report for 1999 from the Institute for 1999 from the Institute for Scientific Information Inc. For one for Scientific Information Inc. For one journal in the CMD series and for four journal in the CMD series and for four journals in the non-CMD series it was not journals in the non-CMD series it was not possible to obtain impact factors and so possible to obtain impact factors and so these have not been included. Using these have not been included. Using Medline, we systematically searched for Medline, we systematically searched for the number of Medline listings for each the number of Medline listings for each author in both the CMD and non-CMD author in both the CMD and non-CMD author series. This permits us to offer three author series. This permits us to offer three estimates of literature impact. First, we estimates of literature impact. First, we have estimated the mean number of Medhave estimated the mean number of Medline listings for a CMD author versus a line listings for a CMD author versus a non-CMD author, giving an estimate of non-CMD author, giving an estimate of author impact. Second, we have assumed author impact. Second, we have assumed the total number of Medline listings for the total number of Medline listings for all authors of an article and multiplied by all authors of an article and multiplied by the journal impact factor; taking a mean the journal impact factor; taking a mean of these values for all articles in a respective of these values for all articles in a respective series gives a literature profile per article series gives a literature profile per article from each series. Third, we have multiplied from each series. Third, we have multiplied the mean literature profile per article, as the mean literature profile per article, as calculated above, by the number of articles calculated above, by the number of articles in each series to give an annual literature in each series to give an annual literature impact factor for both the CMD and nonimpact factor for both the CMD and non-CMD series. CMD series.
The impact factor of a journal and the The impact factor of a journal and the Medline listings linked to academic authors Medline listings linked to academic authors give an estimate of the potential impact of give an estimate of the potential impact of an article, and as such can be expected to an article, and as such can be expected to guide the considerations of a company such guide the considerations of a company such as CMD, which 'strives to exceed the exas CMD, which 'strives to exceed the expectations' of their clients and 'assist them pectations' of their clients and 'assist them in achieving their strategic objectives' in achieving their strategic objectives' (http://www.cmdconnect.com). The actual (http://www.cmdconnect.com). The actual impact of an article may, however, differ impact of an article may, however, differ significantly from its apparent potential. significantly from its apparent potential. We have therefore also established the acWe have therefore also established the actual citation rates for the articles in both tual citation rates for the articles in both series using the Institute for Science series using the Institute for Science Information Web of Science database. For Information Web of Science database. For citation rates we have restricted the comcitation rates we have restricted the comparison to articles from both series that parison to articles from both series that were published in 1998. were published in 1998.
In this study, the appearance of an indiIn this study, the appearance of an individual's name on an article is designated vidual's name on an article is designated as an authorship. An individual author, as an authorship. An individual author, therefore, may have several authorships. therefore, may have several authorships.
RESULTS RESULTS
Using Medline with sertraline as a keyword Using Medline with sertraline as a keyword and searching article titles we found 59 and searching article titles we found 59 distinct articles in 1998 with sertraline in distinct articles in 1998 with sertraline in the title. Altogether for 1998, 1999 and the title. . In 1998, 12 of the 20 articles appearing in the CMD document appeared appearing in the CMD document appeared in the Medline search. Of the eight not in the Medline search. Of the eight not appearing in Medline, five came from the appearing in Medline, five came from the only supplement in the CMD series and only supplement in the CMD series and three from health economics journals; none three from health economics journals; none of these eight articles had sertraline in their of these eight articles had sertraline in their title. title.
Non-CMD articles Non-CMD articles
Excluding from the Medline series those Excluding from the Medline series those articles listed by CMD leaves 47 papers articles listed by CMD leaves 47 papers that included sertraline in the title. We have that included sertraline in the title. We have excluded a further ten papers as follows. excluded a further ten papers as follows. One was a Pfizer-funded large multi-centre One was a Pfizer-funded large multi-centre study that outlined therapeutic advantages study that outlined therapeutic advantages for sertraline in depression. The nature of for sertraline in depression. The nature of this paper and its funding suggest an overthis paper and its funding suggest an overlap with the CMD series of articles laid lap with the CMD series of articles laid out below, in that the data are proprietary. out below, in that the data are proprietary. This article has not been counted in either This article has not been counted in either series. Eight papers that deal with animal, series. Eight papers that deal with animal, healthy volunteer or non-therapeutic metahealthy volunteer or non-therapeutic metabolic research were excluded, as was one bolic research were excluded, as was one letter that offered a comment on the letter that offered a comment on the methodology of a sertraline trial. methodology of a sertraline trial. This leaves 37 papers dealing with the This leaves 37 papers dealing with the therapeutic effects of sertraline. In addition therapeutic effects of sertraline. In addition to those articles retrieved by Medline, we to those articles retrieved by Medline, we have included a further four E have included a further four EMBASE MBASE--listed papers not found in the CMD listed papers not found in the CMD document. E document. EMBASE MBASE also retrieved a also retrieved a further seven papers on toxicology and further seven papers on toxicology and three on biochemical studies, which are three on biochemical studies, which are not considered further. not considered further.
Thus, in total, there are 41 non-CMD Thus, in total, there are 41 non-CMD articles on therapeutics with sertraline: 19 articles on therapeutics with sertraline: 19 are categorised by the Medline retrieval are categorised by the Medline retrieval process as journal articles or clinical trials; process as journal articles or clinical trials; 16 are categorised as letters; and 6 are cate-16 are categorised as letters; and 6 are categorised as randomised controlled trials. Of gorised as randomised controlled trials. Of the 41 articles, 3 report ambiguous findings the 41 articles, 3 report ambiguous findings for sertraline, 20 report negative findings for sertraline, 20 report negative findings and 18 report positive findings, including and 18 report positive findings, including positive results for depression (3), for positive results for depression (3), for premature ejaculation (2) and for dialysis premature ejaculation (2) and for dialysis hypotension (1). Of the 41 non-CMD hypotension (1). Of the 41 non-CMD studies, three received support from Pfizer studies, three received support from Pfizer but the authors appeared likely to be in but the authors appeared likely to be in possession of the raw data. possession of the raw data.
Of the 20 papers offering negative findOf the 20 papers offering negative findings for sertraline, 16 detail adverse effects, ings for sertraline, 16 detail adverse effects, including serotonin syndrome, hypomania, including serotonin syndrome, hypomania, hyponatraemia, suicide attempts, extrahyponatraemia, suicide attempts, extrapyramidal problems, urinary retention and pyramidal problems, urinary retention and priapism. There were, in addition, one repriapism. There were, in addition, one review paper on extrapyramidal problems asview paper on extrapyramidal problems associated with sertaline use and one negative sociated with sertaline use and one negative trial on the use of sertraline in chronic pain. trial on the use of sertraline in chronic pain.
Five of the 41 papers appeared in the Five of the 41 papers appeared in the Journal of Clinical Psychopharmacology Journal of Clinical Psychopharmacology, , three in the three in the Journal of Clinical Psychiatry Journal of Clinical Psychiatry, , two in two in Psychosomatics Psychosomatics, one in the , one in the AmeriAmerican Journal of Psychiatry can Journal of Psychiatry and the rest in a and the rest in a number of lower-impact journals, including number of lower-impact journals, including some non-English-language journals. There some non-English-language journals. There were 121 authorships from 120 individual were 121 authorships from 120 individual authors and an average of 2.95 authors authors and an average of 2.95 authors per article. These articles were 3.4 pages per article. These articles were 3.4 pages in length on average. in length on average.
The CMD articles The CMD articles
The CMD's document outlined 85 papers The CMD's document outlined 85 papers in the production process during 1998: in the production process during 1998: two appeared in 1998 but have a 1997 date two appeared in 1998 but have a 1997 date (these are excluded from the analysis); 20 (these are excluded from the analysis); 20 appeared in 1998; 18 appeared in 1999; appeared in 1998; 18 appeared in 1999; and 17 appeared in 2000 or early 2001. and 17 appeared in 2000 or early 2001. We have used the results for all these We have used the results for all these articles published from 1998 to 2000 to articles published from 1998 to 2000 to generate mean impact factors for authors, generate mean impact factors for authors, journals and articles, but have generated journals and articles, but have generated the overall annual literature impact for the the overall annual literature impact for the CMD series from the articles published in CMD series from the articles published in 1998 alone. 1998 alone.
The 85 articles cover depression (14), The 85 articles cover depression (14), seasonal affective disorders (1), dysthymia seasonal affective disorders (1), dysthymia (7), panic disorder (8), post-traumatic stress (7), panic disorder (8), post-traumatic stress disorder (2), general anxiety (2), obsessivedisorder (2), general anxiety (2), obsessivecompulsive disorder (1), differentiation compulsive disorder (1), differentiation between selective serotonin reuptake between selective serotonin reuptake inhibitors (17), what is termed 'outcomes inhibitors (17), what is termed 'outcomes research' (largely pharmaco-economic research' (largely pharmaco-economic articles) (10), the use of sertraline in articles) (10), the use of sertraline in the elderly (10), the use of sertraline in the elderly (10), the use of sertraline in children (6), the use of sertraline in women children (6), the use of sertraline in women (4), sertraline pharmacokinetics (2) and (4), sertraline pharmacokinetics (2) and sertraline in paedophilia (1). sertraline in paedophilia (1).
The 55 published articles that form the The 55 published articles that form the basis of this analysis have a mean length of basis of this analysis have a mean length of 10.7 pages, with 365 authorships drawn 10.7 pages, with 365 authorships drawn from a total of 207 individual authors, from a total of 207 individual authors, giving a mean of 6.6 authors per article. giving a mean of 6.6 authors per article. Of these, there are 182 academic and 25 Of these, there are 182 academic and 25 company authors. Two of these articles company authors. Two of these articles follow current journal guidelines and follow current journal guidelines and acknowledge writing support from indiviacknowledge writing support from individuals not listed as authors. These 55 articles duals not listed as authors. These 55 articles offer the results of 25 clinical trials from a offer the results of 25 clinical trials from a number of different therapeutic areas, number of different therapeutic areas, including areas in which Pfizer were seekincluding areas in which Pfizer were seeking licenses at that time for sertraline, in ing licenses at that time for sertraline, in addition to eight review articles and six addition to eight review articles and six articles offering economic models based articles offering economic models based on Pfizer trial data. All of the clinical trial on Pfizer trial data. All of the clinical trial results were favourable to Pfizer, as were results were favourable to Pfizer, as were the economic analyses. One of the review the economic analyses. One of the review articles, from a Pfizer author, offered a articles, from a Pfizer author, offered a frank acknowledgement of the capacity of frank acknowledgement of the capacity of sertraline to induce agitation/akathisia and sertraline to induce agitation/akathisia and the links between this and treatmentthe links between this and treatmentinduced suicidality (Lane, 1998) . (This induced suicidality (Lane, 1998) . (This may be because the intention of Lane's may be because the intention of Lane's paper was to place the clinical problem in paper was to place the clinical problem in context rather than to identify specific context rather than to identify specific problems.) The 55 papers appeared in the problems.) The 55 papers appeared in the journals listed in Of the 85 articles, 23 are listed as possOf the 85 articles, 23 are listed as possibly originating within communications ibly originating within communications agencies. Of the 55 published articles, the agencies. Of the 55 published articles, the names of several academic authors appear names of several academic authors appear on more than one article, with one indivion more than one article, with one individual being named as a co-author on 12 of dual being named as a co-author on 12 of these articles. Of the published articles, 13 these articles. Of the published articles, 13 of the 55 do not appear to have a company of the 55 do not appear to have a company author or to have been through an agency. author or to have been through an agency. Four of these 13 articles involve economic Four of these 13 articles involve economic models based on data provided by Pfizer, models based on data provided by Pfizer, and it is assumed that these authors do and it is assumed that these authors do not have access to raw data. Five of the not have access to raw data. Five of the 13 are review articles appearing in a 13 are review articles appearing in a company-sponsored symposium supplecompany-sponsored symposium supplement. The remaining four articles acknowlment. The remaining four articles acknowledge support funding, of which three edge support funding, of which three involve clinical trials. Of these three trials, involve clinical trials. Of these three trials, Pfizer personnel are listed as having rePfizer personnel are listed as having reviewed draft articles in two, but the authors viewed draft articles in two, but the authors appear to hold the data. appear to hold the data.
Comparison of CMD Comparison of CMD and non^CMD articles and non^CMD articles
In Table 2 we list the mean number of In Table 2 we list the mean number of authors per article, the mean number authors per article, the mean number of pages per article and the mean number of pages per article and the mean number of Medline listings per author for each of Medline listings per author for each series. There are statistically significant series. There are statistically significant 2 4 2 4 0.001; 95% CI for the difference between the series CI for the difference between the series was 11.2-42.4) and in terms of the literawas 11.2-42.4) and in terms of the literature profile per article ( ture profile per article (P P4 40.002; 95% CI 0.002; 95% CI for the difference between the series was for the difference between the series was 623-2570). 623-2570).
In addition to the above, we have deterIn addition to the above, we have determined the citation rates for the CMD and mined the citation rates for the CMD and non-CMD series of articles. We have comnon-CMD series of articles. We have compared the CMD articles both with the mean pared the CMD articles both with the mean citation rates for the whole non-CMD citation rates for the whole non-CMD series ( series (n n¼37) and for the non-CMD series 37) and for the non-CMD series with the letters excluded ( with the letters excluded (n n¼23). In each 23). In each case, there is a significant difference becase, there is a significant difference between the data-sets. Using a paired tween the data-sets. Using a paired t t-test, -test, the difference between the two series was the difference between the two series was statistically significant at statistically significant at P P4 40.001 (95% 0.001 (95% CI for the difference between the series CI for the difference between the series was 9.6-22.7). Comparing the CMD series was 9.6-22.7). Comparing the CMD series with the non-CMD series excluding letters with the non-CMD series excluding letters gives a result of gives a result of P P4 40.001 (95% CI 0.001 (95% CI for the difference between the series was for the difference between the series was 7.1-20.8). 7.1-20.8).
In addition, in the non-CMD series In addition, in the non-CMD series there was a mean journal impact factor of there was a mean journal impact factor of 3.0 (95% CI 2-4) for articles reporting 3.0 (95% CI 2-4) for articles reporting beneficial effects of sertraline, versus 1.78 beneficial effects of sertraline, versus 1.78 (95% CI 1-2.5) for those reporting nega-(95% CI 1-2.5) for those reporting negative effects. The mean literature profile for tive effects. The mean literature profile for favourable articles was 351 (95% CI 59-favourable articles was 351 (95% CI 59-643), versus 172 (95% CI 1.7-337) for 643), versus 172 (95% CI 1.7-337) for negative articles. negative articles.
Finally, when the CMD articles were Finally, when the CMD articles were considered on their own, there was a statisconsidered on their own, there was a statistically significant correlation between tically significant correlation between journal impact factors and citation rates journal impact factors and citation rates ( (r r¼0.67; 0.67; P P4 40.01). When both CMD and 0.01). When both CMD and non-CMD articles for 1998 were considnon-CMD articles for 1998 were considered, there was a significant correlation ered, there was a significant correlation between journal impact factor and citation between journal impact factor and citation rates ( rates (r r¼0.71; 0.71; P P4 40.01), which increased 0.01), which increased further if the letters in the non-CMD series further if the letters in the non-CMD series were excluded ( were excluded (r r¼0.74; 0.74; P P4 40.01). There 0.01). There were comparable statistically significant were comparable statistically significant correlations between citation rates and the correlations between citation rates and the composite potential literature profile composite potential literature profile measures that we constructed, as well as measures that we constructed, as well as between journal impact factors and the between journal impact factors and the composite potential literature profile composite potential literature profile measures. measures.
DISCUSSION DISCUSSION
These data address two issues in the scientiThese data address two issues in the scientific literature. First, they offer a further fic literature. First, they offer a further quantification of the number and impact quantification of the number and impact of articles based on proprietary data, and of articles based on proprietary data, and the possible extent of ghostwriting based the possible extent of ghostwriting based on a single drug. Second, they offer a first on a single drug. Second, they offer a first set of figures on the likely impact of a series set of figures on the likely impact of a series of articles prior to publication and the of articles prior to publication and the subsequent citation rates of those articles. subsequent citation rates of those articles.
Literature impact Literature impact
In the debate on how to evaluate the scienIn the debate on how to evaluate the scientific literature, Seglen (1992) has argued tific literature, Seglen (1992) has argued that citation rates rather than journal that citation rates rather than journal impact factors should be used. We have impact factors should be used. We have used both measures and, in addition, a used both measures and, in addition, a composite literature impact measure. The composite literature impact measure. The debate on how to evaluate articles has debate on how to evaluate articles has hitherto focused on the extent to which hitherto focused on the extent to which scientific articles may or may not have scientific articles may or may not have moved a scientific field forward. Citation moved a scientific field forward. Citation rates arguably reflect the true scientific rates arguably reflect the true scientific worth of an article better than the impact worth of an article better than the impact factor of a journal. However, in the field factor of a journal. However, in the field of therapeutics, pharmaceutical companies of therapeutics, pharmaceutical companies may be more interested in short-term gains may be more interested in short-term gains with major purchasers than in developing with major purchasers than in developing the science base of the field. To the extent the science base of the field. To the extent that this is happening, the prestige of that this is happening, the prestige of journals and their apparent authors will journals and their apparent authors will be of greater importance to them than the be of greater importance to them than the actual citation rates of articles. Indeed, in actual citation rates of articles. Indeed, in a mirror image of Seglen's arguments for a mirror image of Seglen's arguments for other scientific domains, citation rates seem other scientific domains, citation rates seem at risk of being artificially boosted by at risk of being artificially boosted by ghostwriters for companies in a way that ghostwriters for companies in a way that is less likely to happen for journal impact is less likely to happen for journal impact factors. The findings reported here, howfactors. The findings reported here, however, appear unaffected by the method used ever, appear unaffected by the method used to evaluate the respective literatures. to evaluate the respective literatures.
The profile of the articles reported here The profile of the articles reported here suggests that the background of certain suggests that the background of certain authors may have increased the possibility authors may have increased the possibility of the company's publications appearing of the company's publications appearing in the most prestigious journals. Specific in the most prestigious journals. Specific journals seem to have been targeted. The journals seem to have been targeted. The combination of distinguished journal, combination of distinguished journal, distinguished author, an efficient distridistinguished author, an efficient distribution system and sponsored platforms bution system and sponsored platforms appears to have led to an impact on the appears to have led to an impact on the therapeutics domain greatly in excess of therapeutics domain greatly in excess of 50% of the impact of the rest of the litera-50% of the impact of the rest of the literature on sertraline. The impact of this literature ture on sertraline. The impact of this literature on third-party payers and other interested on third-party payers and other interested parties is at present unquantifiable. The parties is at present unquantifiable. The question of literature impact would question of literature impact would seem to be tied closely to the nature of seem to be tied closely to the nature of ghostwriting. Authorship lines from perghostwriting. Authorship lines from perceived opinion-leaders with minimal comceived opinion-leaders with minimal company representation and non-declaration pany representation and non-declaration of other non-academic authorship inputs of other non-academic authorship inputs increase the likelihood that these articles increase the likelihood that these articles will be influential with prescribers and will be influential with prescribers and purchasers. purchasers.
Effect of ghostwriting on academia Effect of ghostwriting on academia
One of the expressed concerns about ghostOne of the expressed concerns about ghostwriting has been the way in which this prowriting has been the way in which this process leads to a lack of recognition for the cess leads to a lack of recognition for the people who actually write the articles. The people who actually write the articles. The converse of this point is that academics converse of this point is that academics become opinion leaders in a therapeutics become opinion leaders in a therapeutics field because they appear to have their field because they appear to have their names on a larger proportion of the literanames on a larger proportion of the literature appearing in the most prestigious ture appearing in the most prestigious journals than do others and because they journals than do others and because they get asked to national and international get asked to national and international meetings to present data with which they meetings to present data with which they may not have first-hand acquaintance. may not have first-hand acquaintance. Whether or not the academic authors in this Whether or not the academic authors in this series saw the raw data from the studies the series saw the raw data from the studies the CMD articles are based on, these authors CMD articles are based on, these authors cannot share proprietary raw data with cannot share proprietary raw data with colleagues in the way that has been colleagues in the way that has been traditional in the scientific domain. This, traditional in the scientific domain. This, allied to the volume of industry-linked allied to the volume of industry-linked authorship, indicates a process of changing authorship, indicates a process of changing scientific authorship that could conceivably scientific authorship that could conceivably culminate in a situation in which the domiculminate in a situation in which the dominant figures in therapeutics actually have nant figures in therapeutics actually have comparatively little first-hand research comparatively little first-hand research experience and few raw data that they can experience and few raw data that they can share with others. share with others.
It should be acknowledged that there It should be acknowledged that there are a number of good aspects to the ghostare a number of good aspects to the ghostwriting process. First, authorship by a writing process. First, authorship by a communications agency or within a communications agency or within a company makes it more likely that at least company makes it more likely that at least some of the results of research will enter some of the results of research will enter the public domain than if the production the public domain than if the production of articles were left to the senior clinicians of articles were left to the senior clinicians involved in clinical trials. Second, the involved in clinical trials. Second, the quality of the writing is probably consisquality of the writing is probably consistently superior as a consequence. Third, tently superior as a consequence. Third, there is every reason to believe that at least there is every reason to believe that at least some communications agencies will take some communications agencies will take the efforts by journal editors to encourage the efforts by journal editors to encourage disclosure of interests more seriously than disclosure of interests more seriously than many academic investigators will. Fourth, many academic investigators will. Fourth, there are data to indicate that the reporting there are data to indicate that the reporting of adverse events in company-sponsored of adverse events in company-sponsored and monitored clinical trials is more and monitored clinical trials is more comprehensive than the reporting of comprehensive than the reporting of adverse events in government-sponsored adverse events in government-sponsored or other independent studies (Shamoo, or other independent studies (Shamoo, 2001) . 2001).
However, analyses of published results However, analyses of published results on antidepressant studies in recent years on antidepressant studies in recent years have made it clear that a considerable prohave made it clear that a considerable proportion of negative results are not pubportion of negative results are not published, to the extent that the sponsorship lished, to the extent that the sponsorship of a published study is now a demonstrable of a published study is now a demonstrable predictor of the findings of that study (Freepredictor of the findings of that study (Freemantle mantle et al et al, 2000; Gilbody & Song, 2000) . , 2000; Gilbody & Song, 2000) . There is, however, little reason to believe There is, however, little reason to believe that this bias does not affect the entire that this bias does not affect the entire domain of therapeutics, including psydomain of therapeutics, including psychotherapy, whether supported by pharmachotherapy, whether supported by pharmaceutical companies or not. The tensions ceutical companies or not. The tensions involved show in the figures reported here. involved show in the figures reported here. On the one hand, the CMD-linked articles On the one hand, the CMD-linked articles report universally positive results. On the report universally positive results. On the other hand, the CMD-linked articles other hand, the CMD-linked articles contain a much higher proportion of contain a much higher proportion of randomised controlled trials, conventionrandomised controlled trials, conventionally seen as offering a superior calibre of ally seen as offering a superior calibre of data, than do the non-CMD articles. data, than do the non-CMD articles.
Problems with ghostwriting Problems with ghostwriting
If the methods employed in industry-linked If the methods employed in industry-linked authorship make the publication process authorship make the publication process both more efficient and more effective, then both more efficient and more effective, then what, if any, are the problems linked to what, if any, are the problems linked to new styles of authorship? In addition to new styles of authorship? In addition to having the potential to produce a set of having the potential to produce a set of authorities on therapeutics with little authorities on therapeutics with little clinical experience, we list two other issues. clinical experience, we list two other issues. First, most studies are now sponsored, First, most studies are now sponsored, designed and analysed, in addition to being designed and analysed, in addition to being efficiently written, by pharmaceutical efficiently written, by pharmaceutical companies. This is a process that in psychocompanies. This is a process that in psychopharmacology picked up pace from 1980 pharmacology picked up pace from 1980 (Healy, 2002 (Healy, 2002a . As long as the greatest ). As long as the greatest proportion of studies are both undertaken proportion of studies are both undertaken by and published by pharmaceutical by and published by pharmaceutical companies, the primary questions being companies, the primary questions being asked in the therapeutics domain may well asked in the therapeutics domain may well relate to the marketing interests of those relate to the marketing interests of those companies rather than to unanswered companies rather than to unanswered scientific questions, as the CMD series of scientific questions, as the CMD series of articles outlined here demonstrates. Recent articles outlined here demonstrates. Recent efforts to encourage pharmaceutical efforts to encourage pharmaceutical companies to publish the results of all of companies to publish the results of all of their studies imply that therapeutics will their studies imply that therapeutics will become scientific if all studies are pubbecome scientific if all studies are published. Complete publication of studies lished. Complete publication of studies would, in fact, only bring the field of would, in fact, only bring the field of therapeutics up to an acceptable business therapeutics up to an acceptable business ethics standard. A field is only scientific if ethics standard. A field is only scientific if scientific questions are addressed. scientific questions are addressed.
The second issue relates to the correThe second issue relates to the correspondence between published articles and spondence between published articles and raw data. The current CMD series throws raw data. The current CMD series throws up issues of concern in this area. First, up issues of concern in this area. First, one study in this series had one patient on one study in this series had one patient on sertraline who committed suicide, and three sertraline who committed suicide, and three others on sertraline who reported increasothers on sertraline who reported increasing suicidal ideation necessitating treatment ing suicidal ideation necessitating treatment discontinuation, in contrast to just one case discontinuation, in contrast to just one case of emergent suicidality on a comparable of emergent suicidality on a comparable drug and no problems on placebo. There drug and no problems on placebo. There is no reference to these data in the final is no reference to these data in the final published article. Second, of the six published article. Second, of the six published paediatric psychopharmacology published paediatric psychopharmacology CMD articles, only one article mentions CMD articles, only one article mentions one suicidal act. There were in fact six one suicidal act. There were in fact six suicidal acts on sertraline and three further suicidal acts on sertraline and three further cases of suicidality in the subject group cases of suicidality in the subject group from which these articles come, including from which these articles come, including four suicidal acts in 44 patients with four suicidal acts in 44 patients with depression given sertraline, which is a depression given sertraline, which is a rate of 9% (Pfizer Expert Report, 1997). rate of 9% (Pfizer Expert Report, 1997). The effects of sertraline in paediatric deThe effects of sertraline in paediatric depression were outlined by Alderman pression were outlined by Alderman et al et al (1998) , who reported only the adverse (1998), who reported only the adverse events that occurred in more than 10% of events that occurred in more than 10% of patients. patients.
Attention has previously been drawn to Attention has previously been drawn to possible incongruities in the reporting of possible incongruities in the reporting of suicidal acts on recent antidepressants in a suicidal acts on recent antidepressants in a meta-analysis by Khan meta-analysis by Khan et al et al (2000 Khan et al et al ( ) (see (2000 (see Healy, 2002 Healy, 2002b . Importantly, the categorisa-). Importantly, the categorisation of suicidal acts on placebo from these tion of suicidal acts on placebo from these trials reported by Khan trials reported by Khan et al et al is also reported is also reported in a number of other articles, suggesting in a number of other articles, suggesting that these academic authors may all be that these academic authors may all be using data previously tabulated by the using data previously tabulated by the respective companies. This has clear implirespective companies. This has clear implications for any assessment of the hazards cations for any assessment of the hazards of these drugs, and for the confidence that of these drugs, and for the confidence that can be placed in the process by which these can be placed in the process by which these articles were written. articles were written.
A possible solution A possible solution
Problems of this sort could be overcome if, Problems of this sort could be overcome if, in addition to making available the gross dein addition to making available the gross details of negative studies, as some companies tails of negative studies, as some companies In the absence of clear agreement on how to assess the impact of academic articles, it is not possible to know for certain the relative longer-term impact of articles, it is not possible to know for certain the relative longer-term impact of company-supported articles versus independent articles. company-supported articles versus independent articles. do, companies also made the raw data or do, companies also made the raw data or primary data tables from therapeutic trials primary data tables from therapeutic trials available. This may be seen as a counsel of available. This may be seen as a counsel of perfection, but if pharmacotherapy is to be perfection, but if pharmacotherapy is to be a scientific business rather than just a busia scientific business rather than just a business adopting the appearances of science, ness adopting the appearances of science, no less than this is needed. It should be no less than this is needed. It should be remembered that the capitalisation of the remembered that the capitalisation of the industry depends entirely on the voluntary industry depends entirely on the voluntary participation of health care consumers in participation of health care consumers in studies of the kind reviewed here. If ghoststudies of the kind reviewed here. If ghostwriting is an inevitable feature of modern writing is an inevitable feature of modern scientific writing, the potential availability scientific writing, the potential availability of the raw data would do more to ensure a of the raw data would do more to ensure a correspondence between those data and a correspondence between those data and a published end result than could be achieved published end result than could be achieved by any other mechanism. by any other mechanism.
